Viyash Scientific
Drug Manufacturers - Specialty & Generic · VIYASH
Mid CapHealthcareHigh Growth
Rajaram Narayanan
Managing Director and CEO · Transformational
Company DNA
Performance-Driven
About
Viyash Scientific is a Mid Cap company in the Healthcare sector, listed on NSE as VIYASH. With a market cap of ₹8K Cr and revenue of ₹2K Cr, it is currently in the High Growth phase. Known for its Performance-Driven culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. Focus on high-growth scaling in pharmaceutical generics, led by a professional CEO managing private equity-backed expansion. Its strategic mandate: As a relatively newer player in the pharma space, the firm requires a leader to drive R&D and navigate complex global regulatory landscapes for market entry.
FAQ
What kind of company is Viyash Scientific?
Viyash Scientific is a Mid Cap Healthcare company (VIYASH) in the High Growth phase with a market cap of ₹8K Cr. It is classified as Performance-Driven in culture.
What is Viyash Scientific's culture and work environment like?
Viyash Scientific has a Performance-Driven culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Focus on high-growth scaling in pharmaceutical generics, led by a professional CEO managing private equity-backed expansion.
Who leads Viyash Scientific?
Viyash Scientific is led by Rajaram Narayanan (Managing Director and CEO), a Transformational leader with 35 years of experience.
What are Viyash Scientific's financials?
Viyash Scientific reported revenue of ₹2K Cr in FY25 with a 5-year revenue CAGR of 3.1%. Operating margin: 7.7%. Market cap: ₹8K Cr.
Culture & Strategy
CulturePerformance-Driven
InnovationFast-Follower
PaceStartup-Speed
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandTechnical-Expert
LifecycleHigh Growth
Focus on high-growth scaling in pharmaceutical generics, led by a professional CEO managing private equity-backed expansion.
Mandate
As a relatively newer player in the pharma space, the firm requires a leader to drive R&D and navigate complex global regulatory landscapes for market entry.
As a relatively newer player in the pharma space, the firm requires a leader to drive R&D and navigate complex global regulatory landscapes for market entry.
Financials
Revenue FY25₹2K Cr
PAT FY25₹22 Cr
Rev CAGR 5Y3.1%
OPM7.7%
NPM1.4%
ROE3.1%
ROCE10.9%
P/E76.5
Fwd P/E20.3
P/B6.1
D/E55.3
Mkt Cap₹8K Cr
Promoter67.9%
Institutional7.3%
Similar Culture
Could You Lead Viyash Scientific?
Take the Genome Benchmark →